Google Halts UK YouTube TV Measurement Service After Legal Action 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
MENLO PARK, Calif., May 22, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference.
| Event: | Jefferies Global Healthcare Conference |
| Date: | June 7, 2017 |
| Time: | 1:30 – 2:00 p.m. ET |
| Location: | New York, NY |
A live and replay video webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Contacts for Adverum: Leone Patterson Chief Financial Officer Adverum Biotechnologies, Inc. 650-665-7222 [email protected] Tricia Truehart Vice President The Trout Group LLC 646-378-2953 [email protected]
